RetroSense Therapeutics
Ann Arbor
About RetroSense Therapeutics
RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $17.1M
- Funding stage: M&A
- Last round: Series B (Nov 2015)
- Website: retro-sense.com
- Phone: (734) 369-9333
Industries & Categories
Biotechnology, Genetics, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/retrosense-therapeutics-3011710 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.